Curis, Inc.
Curis, Inc. (Nasdaq: CRIS) is a biotechnology company developing emavusertib, an orally available small-molecule inhibitor of IRAK4 and FLT3, for hematologic cancers. The drug candidate is being evaluated with ibrutinib in a Phase 1/2 study for relapsed or refractory primary central nervous system lymphoma and with… From the company’s description.
Over the twelve months to Jun 30, 2026, Curis, Inc. reported revenue of $4.31M, down 62.2% from a year earlier, and a net loss of $21.15M. Its operating margin was −203.2%, and operations used $30.59M in cash. In fiscal 2025, it reported revenue of $9.44M, down 13.4% from fiscal 2024, and a net loss of $7.58M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Curis, Inc. does
In the company’s own words
Curis, Inc. (Nasdaq: CRIS) is a biotechnology company developing emavusertib, an orally available small-molecule inhibitor of IRAK4 and FLT3, for hematologic cancers. The drug candidate is being evaluated with ibrutinib in a Phase 1/2 study for relapsed or refractory primary central nervous system lymphoma and with zanubrutinib in a Phase 2 study for chronic lymphocytic leukemia; its acute myeloid leukemia studies are substantially complete. Curis licenses emavusertib from Aurigene Discovery Technologies under a collaboration that also covers other oncology programs. The company has no reportable business segments described in the provided business overview and is focused on drug research and development rather than marketed products. In November 2025, Curis sold its Erivedge-related assets and rights under its Genentech license, ending its entitlement to revenue from that product. Curis had $5.1 million in cash and cash equivalents at December 31, 2025. Its website is www.curis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1108205
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Curis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Curis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Curis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Curis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Curis, Inc.'s last four quarterly filings that the numbers alone won't show?”